This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Grab These 6 Stocks That Boast Substantial Net Profit Margin
by Zacks Equity Research
Here are six stocks with spectacular net profit margin that can contribute to making a winning portfolio.
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.
Focus on 6 Top-Ranked Stocks With Solid Net Profit Margin
by Zacks Equity Research
Here are six marvelous stocks with significant net profit margin that investors can bank on for remarkable returns.
Is Kamada (KMDA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
by Zacks Equity Research
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
Dollar Strengthens on Turkey's Trouble: Top 5 Gainers
by Tirthankar Chakraborty
Lira loses more than 20% over the week as international markets react to the uncertainty over Turkey's capability to repay foreign-currency debts. Dollar hits a one-year high.
Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (KMDA) Outperforming Other Medical Stocks This Year?
4 Undervalued MedTech Stocks to Consider Amid Volatility
by Zacks Equity Research
Amid turbulences of the U.S. market, some value stocks of MedTech industry appear to be lucrative investment options.
Kamada (KMDA) Gets FDA Approval for Rabies Vaccine
by Zacks Equity Research
Kamada Ltd. (KMDA) and partner Kedrion Biopharma and announced that FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection.
Kamada Withdraws Inhaled AAT Marketing Application in EU
by Zacks Equity Research
Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.
Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
by Zacks Equity Research
Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.
Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
by Zacks Equity Research
Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.
Allergan Natrelle Inspira Breast Implants Approved in the U.S.
by Zacks Equity Research
Allergan plc (AGN) announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.
Sanofi (SNY) Closes Business Exchange Deal with Boehringer
by Zacks Equity Research
Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.